Literature DB >> 8397142

Redox cycling of MPP+: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase.

L K Klaidman1, J D Adams, A C Leung, S S Kim, E Cadenas.   

Abstract

MPP+ is redox active in the presence of cytochrome P450 reductase and induces the formation of O2.- and HO(.). In this study, we report the redox cycling capability of MPP+ with additional enzymes and with UV photolysis detected through ESR techniques. The treatment of MPP+ with UV light resulted in the production of HO. trapped as a spin adduct. Two of the enzymes examined in this study, xanthine oxidase and aldehyde dehydrogenase, produced O2.- in the presence of substrate. However, when MPP+ was added to the incubations, the radical trapped by DMPO was HO(.). This indicates that MPP+ redox cycles in the presence of these two enzymes or UV light, which produces HO.. Our data also suggest that MPP+ is reduced by lipoamide dehydrogenase. MPP+ stimulated the oxidation of reduced nicotinamide adenine dinucleotide (NADH) by the enzyme at concentrations between 2 mM and 8 mM of MPP+. Higher concentrations of MPP+ inhibited lipoamide dehydrogenase. MPP+ appears to be redox active with a number of redox enzymes. The mechanism involved may be hydride transfer from the enzymes to MPP+, rather than a direct single-electron reduction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397142     DOI: 10.1016/0891-5849(93)90056-z

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  18 in total

Review 1.  Mitochondrial mechanisms of redox cycling agents implicated in Parkinson's disease.

Authors:  Pamela Lopert; Manisha Patel
Journal:  J Neural Transm (Vienna)       Date:  2015-03-07       Impact factor: 3.575

2.  Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: lack of correlation with superoxide generation.

Authors:  Brian P Dranka; Jacek Zielonka; Anumantha G Kanthasamy; Balaraman Kalyanaraman
Journal:  J Neurochem       Date:  2012-07-11       Impact factor: 5.372

Review 3.  Toxin models of mitochondrial dysfunction in Parkinson's disease.

Authors:  Terina N Martinez; J Timothy Greenamyre
Journal:  Antioxid Redox Signal       Date:  2011-07-12       Impact factor: 8.401

4.  Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells.

Authors:  Naomi Matoh; Seigo Tanaka; Masanori Takehashi; Marek Banasik; Todd Stedeford; Eliezer Masliah; Shigehiko Suzuki; Yoshihiko Nishimura; Kunihiro Ueda
Journal:  Gene Expr       Date:  2003

5.  Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

Authors:  William Lin; Un Jung Kang
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

Review 6.  A re-evaluation of the tissue distribution and physiology of xanthine oxidoreductase.

Authors:  A Kooij
Journal:  Histochem J       Date:  1994-12

7.  Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.

Authors:  P Bonsi; D Cuomo; G Martella; G Sciamanna; M Tolu; P Calabresi; G Bernardi; A Pisani
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

8.  Role of aldehyde dehydrogenase 2 in 1-methy-4-phenylpyridinium ion-induced aldehyde stress and cytotoxicity in PC12 cells.

Authors:  Ai-Hua Chen; Ping Zhang; Wei-Lan Yin; Li Wang; Wei Zou; Xiao-Qing Tang
Journal:  Neurochem Res       Date:  2014-07-09       Impact factor: 3.996

9.  Dopamine and its metabolites in cathepsin D heterozygous mice before and after MPTP administration.

Authors:  Donna Crabtree; Michaël Boyer-Guittaut; Xiaosen Ouyang; Naomi Fineberg; Jianhua Zhang
Journal:  Neurosci Lett       Date:  2013-02-04       Impact factor: 3.046

Review 10.  Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice.

Authors:  J L Cadet; S F Ali; R B Rothman; C J Epstein
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.